51
|
Kumar R, Horvath A, Mazumder R, Toi M, Sato F, Pillai MR, Costa L, Carmo-Fonseca M, Knapp S, Dutt A, Gupta S, Badwe R. The Global Cancer Genomics Consortium’s Second Annual Symposium. Genes Cancer 2013; 4. [PMCID: PMC3782003 DOI: 10.1177/1947601913484582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The Second Annual Symposium of the Global Cancer Genomics Consortium (GCGC) was held at the Tata Memorial Center in Mumbai, India, from November 19 to 20, 2012. Founded in late 2010, the GCGC aims to provide a platform for highly productive, collaborative efforts on next-generation cancer research through bridging the latest scientific and technology developments with clinical oncology challenges. This year’s presenters brought together highly innovative interdisciplinary views and strategies to meet major challenges in cancer research. The symposium featured 3 major themes: OMICS approaches toward the identification of cancer molecular drivers, single-cell analysis in cancer, and clinical and translational genomics. Each theme was represented in presentations of new findings, with an obvious implication in cross-disciplinary components of OMICs and an overwhelming participation by students. In summary, the GCGC symposium provided a discussion and congregation of the latest advances in basic and translational cancer research and offered the participants with a highly cooperative network environment for future collaboration.
Collapse
Affiliation(s)
- Rakesh Kumar
- The Global Cancer Genomics Consortium, the McCormick Genomic and Proteomic Center
- Department of Biochemistry and Molecular Medicine, the George Washington University, Washington, DC, USA
| | - Anelia Horvath
- The Global Cancer Genomics Consortium, the McCormick Genomic and Proteomic Center
- Department of Biochemistry and Molecular Medicine, the George Washington University, Washington, DC, USA
| | - Raja Mazumder
- Department of Biochemistry and Molecular Medicine, the George Washington University, Washington, DC, USA
| | - Masakazu Toi
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Fumiaki Sato
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Luis Costa
- Hospital de Santa Maria and Institute of Molecular Medicine, Lisbon, Portugal
| | - Maria Carmo-Fonseca
- Hospital de Santa Maria and Institute of Molecular Medicine, Lisbon, Portugal
| | - Stefan Knapp
- Structural Genomic Consortium, University of Oxford, Oxford, UK
| | | | | | | |
Collapse
|
52
|
Choughule A, Noronha V, Joshi A, Desai S, Jambhekar N, Utture S, Thavamanni A, Prabhash K, Dutt A. Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. Indian J Cancer 2013; 50:107-11. [PMID: 23979200 PMCID: PMC5808828 DOI: 10.4103/0019-509x.117023] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND The Medical Oncology Department at Tata Memorial Hospital, the single largest tertiary cancer care center in Asia, receives in-house registered and referral patient samples from all parts of the country. Our recent studies establish 23% EGFR mutation frequency among Indian population. Here, we extend our study and report further analysis of distribution of different types of EGFR mutations in 1018 non small cell lung cancer patient, and its co-relation with clinical parameters and geographical variations across the country. MATERIAL AND METHODS This study is a retrospective analysis on all the patients who were referred for EFGR testing as a routine service over a 1.5 year period. This was part of standard care. EGFR kinase domain mutations in exon 18-21 were probed by TaqMan probe-based assays in 1018 NSCLC patients. RESULTS AND DISCUSSION While EGFR exon 19 mutations, the most frequent EGFR mutation, were found be higher among non smokers females, we find surprisingly higher incidence of exon 21 mutations among EGFR mutation positive male smokers of Indian ethnicity. Furthermore, as Indian population is known to be composed of a gradient admixture of Ancestral North Indian (with genetic influence from Middle Easterners, Central Asians, and Europeans harboring variant EGFR mutation frequency) and Ancestral South Indians, as a paradox our study indicates comparable EGFR mutation frequency across different geographical locations within India CONCLUSION Geographically there is uniform distribution in the EGFR mutation frequency within India. Further more, while exon 19 mutations are predominant among non smokers, higher incidence of exon 21 mutations exists among EGFR mutation positive male smokers of Indian ethnicity.
Collapse
Affiliation(s)
- A Choughule
- Department of Medical Oncology, Tata Memorial Hospital, Navi Mumbai, Maharashtra, India
| | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N, Dutt A. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One 2013; 8:e76164. [PMID: 24124538 PMCID: PMC3790706 DOI: 10.1371/journal.pone.0076164] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2013] [Accepted: 08/23/2013] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND During the past decade, the incidence of EGFR mutation has been shown to vary across different ethnicities. It occurs at the rate of 10-15% in North Americans and Europeans, 19% in African-Americans, 20-30% in various East Asian series including Chinese, Koreans, and Japanese. Frequency of EGFR mutations in India however remains sparsely explored. METHODOLOGY/PRINCIPAL FINDINGS We report 23% incidence of Epidermal growth factor receptor (EGFR) mutations in 907 Non small cell lung cancer (NSCLC) patients of Indian ethnicity, in contrast to 10-15% known in Caucasians and 27-62% among East Asians. In this study, EGFR mutations were found to be more common in never-smokers 29.4% as compared to smokers 15.3%. Consistent with other populations, mutation rates among adenocarcinoma-males were predominantly lower than females with 32% incidence. However unlike Caucasians, EGFR mutation rate among adenocarcinoma-never-smoker females were comparable to males suggesting lack of gender bias among never smokers likely to benefit from EGFR targeted therapy. CONCLUSIONS/SIGNIFICANCE This study has an overall implication for establishing relevance for routine EGFR mutation diagnostics for NSCLC patients in clinics and emphasizes effectiveness for adoption of EGFR inhibitors as the first line treatment among Indian population. The intermediate frequency of EGFR mutation among Indian population compared to Caucasians and East Asians is reminiscent of an ancestral admixture of genetic influence from Middle Easterners, Central Asians, and Europeans on modern- Indian population that may confer differential susceptibility to somatic mutations in EGFR.
Collapse
Affiliation(s)
- Anuradha Chougule
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India
| | - Kumar Prabhash
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India
- * E-mail: (KP); (AD)
| | - Vanita Noronha
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India
| | - Amit Joshi
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India
| | - Abhishek Thavamani
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, India
| | - Pratik Chandrani
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, India
| | - Pawan Upadhyay
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, India
| | - Sagarika Utture
- Department of Pathology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India
| | - Saral Desai
- Department of Pathology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India
| | - Nirmala Jambhekar
- Department of Pathology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, Maharashtra, India
| | - Amit Dutt
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, Maharashtra, India
- * E-mail: (KP); (AD)
| |
Collapse
|
54
|
Noronha V, Prabhash K, Thavamani A, Chougule A, Purandare N, Joshi A, Sharma R, Desai S, Jambekar N, Dutt A, Mulherkar R. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS One 2013; 8:e61561. [PMID: 23620765 PMCID: PMC3631198 DOI: 10.1371/journal.pone.0061561] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Accepted: 03/11/2013] [Indexed: 02/05/2023] Open
Abstract
Screening for EGFR mutation is a key molecular test for management of lung cancer patients. Outcome of patients with mutation receiving EGFR tyrosine kinase inhibitor is known to be better across different ethnic populations. However, frequency of EGFR mutations and the clinical response in most other ethnic populations, including India, remains to be explored. We conducted a retrospective analysis of Indian lung cancer patients who were managed with oral tyrosine kinase inhibitors. Majority of the patients in the study had adenocarcinoma and were non-smokers. 39/111 patients tested positive for EGFR kinase domain mutations determined by Taqman based real time PCR. The overall response to oral TKI therapy was 30%. Patients with an activating mutation of EGFR had a response rate of 74%, while the response rate in patients with wild type EGFR was 5%, which was a statistically significant difference. Progression free survival of patients with EGFR mutations was 10 months compared to 2 months for EGFR mutation negative patients. Overall survival was 19 months for EGFR mutation patients and 13 months for mutation negative patients. This study emphasizes EGFR mutation as an important predictive marker for response to oral tyrosine kinase inhibitors in the Indian population.
Collapse
Affiliation(s)
- Vanita Noronha
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Kumar Prabhash
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
- * E-mail: (KP); (AD)
| | - Abhishek Thavamani
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Anuradha Chougule
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Nilendu Purandare
- Department of Radiology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Amit Joshi
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Rashmi Sharma
- Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Saral Desai
- Department of Pathology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Nirmala Jambekar
- Department of Pathology, Tata Memorial Hospital, Tata Memorial Center, Mumbai, India
| | - Amit Dutt
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, India
- * E-mail: (KP); (AD)
| | - Rita Mulherkar
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Navi Mumbai, India
| |
Collapse
|
55
|
Abstract
The Global Cancer Genomics Consortium (GCGC) is an international collaborative platform that amalgamates cancer biologists, cutting-edge genomics, and high-throughput expertise with medical oncologists and surgical oncologists; they address the most important translational questions that are central to cancer research and treatment. The annual GCGC symposium was held at the Advanced Centre for Treatment Research and Education in Cancer, Mumbai, India, from November 9 to 11, 2011. The symposium showcased international next-generation sequencing efforts that explore cancer-specific transcriptomic changes, single-nucleotide polymorphism, and copy number variations in various types of cancers, as well as the structural genomics approach to develop new therapeutic targets and chemical probes. From the spectrum of studies presented at the symposium, it is evident that the translation of emerging cancer genomics knowledge into clinical applications can only be achieved through the integration of multidisciplinary expertise. In summary, the GCGC symposium provided practical knowledge on structural and cancer genomics approaches, as well as an exclusive platform for focused cancer genomics endeavors.
Collapse
|
56
|
Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack A, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, Kesari S, Meyerson M. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res 2011; 71:7587-96. [PMID: 22001862 PMCID: PMC3242822 DOI: 10.1158/0008-5472.can-11-0821] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Genomic alterations of the epidermal growth factor receptor (EGFR) gene play a crucial role in pathogenesis of glioblastoma multiforme (GBM). By systematic analysis of GBM genomic data, we have identified and characterized a novel exon 27 deletion mutation occurring within the EGFR carboxyl-terminus domain (CTD), in addition to identifying additional examples of previously reported deletion mutations in this region. We show that the GBM-derived EGFR CTD deletion mutants are able to induce cellular transformation in vitro and in vivo in the absence of ligand and receptor autophosphorylation. Treatment with the EGFR-targeted monoclonal antibody, cetuximab, or the small molecule EGFR inhibitor, erlotinib, effectively impaired tumorigenicity of oncogenic EGFR CTD deletion mutants. Cetuximab in particular prolonged the survival of intracranially xenografted mice with oncogenic EGFR CTD deletion mutants, compared with untreated control mice. Therefore, we propose that erlotinib and, especially, cetuximab treatment may be a promising therapeutic strategy in GBM patients harboring EGFR CTD deletion mutants.
Collapse
Affiliation(s)
- Jeonghee Cho
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Genomic Analysis Center, Samsung Cancer Reseacrh Institute, Samsung Medical Center, Seoul, 135-710, Republic of Korea
| | - Sandra Pastorino
- Department of Neurosciences, Moores Cancer Center, UC San Diego, La Jolla, CA, 92093, USA
| | - Qing Zeng
- Department of Radiology, Brigham and Women’s Hospital, Boston, MA, 02115, USA
| | - Xiaoyin Xu
- Department of Radiology, Brigham and Women’s Hospital, Boston, MA, 02115, USA
| | - William Johnson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
| | | | - Roel Verhaak
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA
| | - Andrew Cherniack
- Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA
| | - Hideo Watanabe
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA
| | - Amit Dutt
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA
| | - Jihyun Kwon
- Genomic Analysis Center, Samsung Cancer Reseacrh Institute, Samsung Medical Center, Seoul, 135-710, Republic of Korea
| | - Ying S. Chao
- Department of Neurosciences, Moores Cancer Center, UC San Diego, La Jolla, CA, 92093, USA
| | | | - Derek Chiang
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA
| | - Yuki Yuza
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA
| | - Santosh Kesari
- Department of Neurosciences, Moores Cancer Center, UC San Diego, La Jolla, CA, 92093, USA
| | - Matthew Meyerson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
- Broad Institute of M.I.T. and Harvard, Cambridge, MA, 02142, USA
| |
Collapse
|
57
|
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland Å, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1:78-89. [PMID: 22328973 PMCID: PMC3274752 DOI: 10.1158/2159-8274.cd-11-0005] [Citation(s) in RCA: 359] [Impact Index Per Article: 27.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
UNLABELLED While genomically targeted therapies have improved outcomes for patients with lung adenocarcinoma, little is known about the genomic alterations which drive squamous cell lung cancer. Sanger sequencing of the tyrosine kinome identified mutations in the DDR2 kinase gene in 3.8% of squamous cell lung cancers and cell lines. Squamous lung cancer cell lines harboring DDR2 mutations were selectively killed by knock-down of DDR2 by RNAi or by treatment with the multi-targeted kinase inhibitor dasatinib. Tumors established from a DDR2 mutant cell line were sensitive to dasatinib in xenograft models. Expression of mutated DDR2 led to cellular transformation which was blocked by dasatinib. A squamous cell lung cancer patient with a response to dasatinib and erlotinib treatment harbored a DDR2 kinase domain mutation. These data suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib. As dasatinib is already approved for use, these findings could be rapidly translated into clinical trials. SIGNIFICANCE DDR2 mutations are present in 4% of lung SCCs, and DDR2 mutations are associated with sensitivity to dasatinib. These findings provide a rationale for designing clinical trials with the FDA-approved drug dasatinib in patients with lung SCCs.
Collapse
Affiliation(s)
- Peter S Hammerman
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Martin L Sos
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
- Department I of Internal Medicine and Laboratory of Translational Cancer Genomics, Center of Integrated Oncology Köln – Bonn, University of Köln, Köln, Germany
| | | | - Chunxiao Xu
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Amit Dutt
- Broad Institute, Cambridge, Massachusetts, USA
| | - Wenjun Zhou
- Department of Biological Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Lear E Brace
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Brittany A Woods
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Wenchu Lin
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Jianming Zhang
- Department of Biological Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Xianming Deng
- Department of Biological Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Sang Min Lim
- Department of Biological Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Stefanie Heynck
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | - Martin Peifer
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | - Jeffrey R Simard
- Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany
| | | | | | - Helga B Salvesen
- Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway
- Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway
| | - Danila Seidel
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | - Thomas Zander
- Department I of Internal Medicine and Laboratory of Translational Cancer Genomics, Center of Integrated Oncology Köln – Bonn, University of Köln, Köln, Germany
- Department I for Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital of Cologne, Germany
| | - Johannes M Heuckmann
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | | | | | - Mirjam Koker
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | - Frauke Leenders
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | - Franziska Gabler
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | - Silvia Querings
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
| | - Sascha Ansén
- Department I for Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital of Cologne, Germany
| | - Elisabeth Brambilla
- Institut Albert Bonniot INSERM U823; Université Joseph Fourier Grenoble France
| | - Christian Brambilla
- Institut Albert Bonniot INSERM U823; Université Joseph Fourier Grenoble France
| | - Philippe Lorimier
- Institut Albert Bonniot INSERM U823; Université Joseph Fourier Grenoble France
| | - Odd Terje Brustugun
- Division of Surgery and Cancer, Oslo University Hospital Radiumhospitalet, Montebello 0301, Oslo, Norway
| | - Åslaug Helland
- Division of Surgery and Cancer, Oslo University Hospital Radiumhospitalet, Montebello 0301, Oslo, Norway
| | - Iver Petersen
- Jena University Hospital, Department Hematology/Oncology, Jena, Germany
| | - Joachim H Clement
- Jena University Hospital, Department Hematology/Oncology, Jena, Germany
| | - Harry Groen
- University Medical Center Groningen and University of Groningen, Pulmonology and Pathology, Groningen, Netherlands
| | - Wim Timens
- University Medical Center Groningen and University of Groningen, Pulmonology and Pathology, Groningen, Netherlands
| | - Hannie Sietsma
- University Medical Center Groningen and University of Groningen, Pulmonology and Pathology, Groningen, Netherlands
| | | | - Jürgen Wolf
- Department I of Internal Medicine and Laboratory of Translational Cancer Genomics, Center of Integrated Oncology Köln – Bonn, University of Köln, Köln, Germany
- Department I for Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital of Cologne, Germany
| | - David G Beer
- Section of Thoracic Surgery, Department of Surgery, Ann Arbor, Michigan, USA
| | - Ming Sound Tsao
- Ontario Cancer Institute and Princess Margaret Hospital, Toronto, Canada
| | - Megan Hanna
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
- Broad Institute, Cambridge, Massachusetts, USA
- Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Charles Hatton
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
- Broad Institute, Cambridge, Massachusetts, USA
- Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Michael J Eck
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Pasi A Janne
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Bruce E Johnson
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | | | - Heidi Greulich
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
- Broad Institute, Cambridge, Massachusetts, USA
| | - Adam J Bass
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Jeonghee Cho
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Daniel Rauh
- Chemical Genomics Centre of the Max Planck Society, Otto-Hahn-Strasse 15, D-44227 Dortmund, Germany
- Technical University Dortmund, Otto-Hahn-Strasse 6, D-44221 Dortmund, Germany
| | - Nathanael S Gray
- Department of Biological Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Kwok-Kin Wong
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| | - Eric B Haura
- Departments of Thoracic Oncology and Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
| | - Roman K Thomas
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Köln, Köln, Germany
- Department I of Internal Medicine and Laboratory of Translational Cancer Genomics, Center of Integrated Oncology Köln – Bonn, University of Köln, Köln, Germany
- Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
| | - Matthew Meyerson
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
- Broad Institute, Cambridge, Massachusetts, USA
- Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts, USA
| |
Collapse
|
58
|
Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6:e20351. [PMID: 21666749 PMCID: PMC3110189 DOI: 10.1371/journal.pone.0020351] [Citation(s) in RCA: 288] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2010] [Accepted: 04/30/2011] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in squamous cell lung carcinoma. METHODOLOGY/PRINCIPAL FINDINGS Using SNP array analysis, we found that a region of chromosome segment 8p11-12 containing three genes-WHSC1L1, LETM2, and FGFR1-is amplified in 3% of lung adenocarcinomas and 21% of squamous cell lung carcinomas. Furthermore, we demonstrated that a non-small cell lung carcinoma cell line harboring focal amplification of FGFR1 is dependent on FGFR1 activity for cell growth, as treatment of this cell line either with FGFR1-specific shRNAs or with FGFR small molecule enzymatic inhibitors leads to cell growth inhibition. CONCLUSIONS/SIGNIFICANCE These studies show that FGFR1 amplification is common in squamous cell lung cancer, and that FGFR1 may represent a promising therapeutic target in non-small cell lung cancer.
Collapse
Affiliation(s)
- Amit Dutt
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Kharghar, Navi Mumbai, India
- * E-mail: (MM); (AD)
| | - Alex H. Ramos
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
- Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America
| | - Peter S. Hammerman
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Craig Mermel
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
| | - Jeonghee Cho
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
| | - Tanaz Sharifnia
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
| | - Ajit Chande
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Center, Kharghar, Navi Mumbai, India
| | - Kumiko Elisa Tanaka
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
| | - Nicolas Stransky
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
| | - Heidi Greulich
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Nathanael S. Gray
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America
| | - Matthew Meyerson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, United States of America
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America
- * E-mail: (MM); (AD)
| |
Collapse
|
59
|
Zhou W, Hur W, McDermott U, Dutt A, Xian W, Picarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M, Settleman J, Gray NS. A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol 2010; 17:285-95. [PMID: 20338520 PMCID: PMC2920453 DOI: 10.1016/j.chembiol.2010.02.007] [Citation(s) in RCA: 110] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2009] [Revised: 01/14/2010] [Accepted: 01/29/2010] [Indexed: 02/08/2023]
Abstract
The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a number of cancers. We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site. We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC(50) = 14 nM) as well as numerous FGFR-dependent cancer cell lines. A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486. FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.
Collapse
Affiliation(s)
- Wenjun Zhou
- Department of Cancer Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Wooyoung Hur
- Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, USA
| | - Ultan McDermott
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA
| | - Amit Dutt
- The Broad Institute, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Wa Xian
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Scott B. Picarro
- Department of Cancer Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Jianming Zhang
- Department of Cancer Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Sreenath V. Sharma
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA
| | - Joan Brugge
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Matthew Meyerson
- The Broad Institute, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Jeffrey Settleman
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA
| | - Nathanael S. Gray
- Department of Cancer Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
- Correspondence: Nathanael S. Gray ()
| |
Collapse
|
60
|
Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009; 8:2042-50. [PMID: 19755855 PMCID: PMC2833355 DOI: 10.4161/cbt.8.21.9764] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
In cancer, proto-oncogenes are often altered by genomic amplification. Here we report recurrent focal amplifications of chromosomal segment 4q12 overlapping the proto-oncogenes PDGFRA and KIT in non-small cell lung cancer (NSCLC). Single nucleotide polymorphism (SNP) array and fluorescent in situ hybridization (FISH) analysis indicate that 4q12 is amplified in 3-7% of lung adenocarcinomas and 8-10% of lung squamous cell carcinomas. In addition, we demonstrate that the NSCLC cell line NCI-H1703 exhibits focal amplification of PDGFRA and is dependent on PDGFRalpha activity for cell growth. Treatment of NCI-H1703 cells with PDGFRA-specific shRNAs or with the PDGFRalpha/KIT small molecule inhibitors imatinib or sunitinib leads to cell growth inhibition. However, these observations do not extend to NSCLC cell lines with lower-amplitude and broader gains of chromosome 4q. Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFRalpha/KIT inhibitors.
Collapse
Affiliation(s)
- Alex H. Ramos
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
- Department of Pathology; Harvard Medical School; Boston, MA USA
| | - Amit Dutt
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
| | - Craig Mermel
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
- Department of Pathology; Harvard Medical School; Boston, MA USA
| | - Sven Perner
- Department of Pathology; University Hospital of Tübingen; Tübingen, Germany
| | - Jeonghee Cho
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
| | | | - Laura A. Johnson
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
| | - Ann-Cathrin Stiedl
- Department of Pathology; University Hospital of Tübingen; Tübingen, Germany
| | - Kumiko E. Tanaka
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
| | - Adam J. Bass
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
| | - Jordi Barretina
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
| | - Barbara A. Weir
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
| | - Rameen Beroukhim
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
| | - Roman K. Thomas
- Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max-Planck Society and the Medical Faculty of the University of Cologne; Cologne, Germany
- Center for Integrated Oncology and Department for Internal Medicine; University of Cologne; Cologne, Germany
| | - John D. Minna
- Hamon Center for Therapeutic Oncology Research-Simmons Cancer Center; and Department of University of Texas Southwestern Medical Center; Dallas, TX USA
- Department of Internal Medicine; University of Texas Southwestern Medical Center; Dallas, TX USA
- Department of Pharmacology; University of Texas Southwestern Medical Center; Dallas, TX USA
| | - Lucian R. Chirieac
- Department of Pathology; Harvard Medical School; Boston, MA USA
- Department of Pathology; Brigham and Women’s Hospital; Boston, MA USA
| | - Neal I. Lindeman
- Department of Pathology; Harvard Medical School; Boston, MA USA
- Department of Pathology; Brigham and Women’s Hospital; Boston, MA USA
| | - Thomas Giordano
- Department of Pathology; University of Michigan; Ann Arbor, MI USA
| | - David G. Beer
- Section of Thoracic Surgery; Department of Surgery; University of Michigan; Ann Arbor, MI USA
| | - Patrick Wagner
- Department of Pathology; Weill Medical College of Cornell University; New York, NY USA
| | - Ignacio I. Wistuba
- Department of Epidemiology; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA
- Department of Pathology; The University of Texas M.D. Anderson Cancer Center; Houston, TX USA
| | - Mark A. Rubin
- Department of Pathology; Weill Medical College of Cornell University; New York, NY USA
| | - Matthew Meyerson
- Department of Medical Oncology and Center for Cancer Genome Discovery; Dana-Farber Cancer Institute; Boston, MA USA
- Cancer Program; Broad Institute of Harvard and MIT; Cambridge, MA USA
- Department of Pathology; Harvard Medical School; Boston, MA USA
- Correspondence to: Matthew Meyerson;
| |
Collapse
|
61
|
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Ribeiro U, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41:1238-42. [PMID: 19801978 PMCID: PMC2783775 DOI: 10.1038/ng.465] [Citation(s) in RCA: 732] [Impact Index Per Article: 48.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2009] [Accepted: 09/11/2009] [Indexed: 02/08/2023]
Abstract
Lineage-survival oncogenes are activated by somatic DNA alterations in cancers arising from the cell lineages in which these genes play a role in normal development. Here we show that a peak of genomic amplification on chromosome 3q26.33 found in squamous cell carcinomas (SCCs) of the lung and esophagus contains the transcription factor gene SOX2, which is mutated in hereditary human esophageal malformations, is necessary for normal esophageal squamous development, promotes differentiation and proliferation of basal tracheal cells and cooperates in induction of pluripotent stem cells. SOX2 expression is required for proliferation and anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference experiments. Furthermore, ectopic expression of SOX2 here cooperated with FOXE1 or FGFR2 to transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors show expression of markers of both squamous differentiation and pluripotency. These characteristics identify SOX2 as a lineage-survival oncogene in lung and esophageal SCC.
Collapse
|
62
|
Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer 2009; 101:1218-9; author reply 1220-1. [PMID: 19738612 PMCID: PMC2768084 DOI: 10.1038/sj.bjc.6605301] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Affiliation(s)
- A Dutt
- Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
- Cancer Program, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
| | - H B Salvesen
- Department of Clinical Medicine, The University of Bergen, Bergen 5020, Norway
- Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen N-5021, Norway
| | - H Greulich
- Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
- Cancer Program, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
- Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
| | - W R Sellers
- Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - R Beroukhim
- Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
- Cancer Program, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
- Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
- E-mail:
| | - M Meyerson
- Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
- Cancer Program, The Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA 02142, USA
- Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
- Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
- E-mail:
| |
Collapse
|
63
|
Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Øyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009; 106:4834-9. [PMID: 19261849 PMCID: PMC2660768 DOI: 10.1073/pnas.0806514106] [Citation(s) in RCA: 221] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Although 75% of endometrial cancers are treated at an early stage, 15% to 20% of these recur. We performed an integrated analysis of genome-wide expression and copy-number data for primary endometrial carcinomas with extensive clinical and histopathological data to detect features predictive of recurrent disease. Unsupervised analysis of the expression data distinguished 2 major clusters with strikingly different phenotypes, including significant differences in disease-free survival. To identify possible mechanisms for these differences, we performed a global genomic survey of amplifications, deletions, and loss of heterozygosity, which identified 11 significantly amplified and 13 significantly deleted regions. Amplifications of 3q26.32 harboring the oncogene PIK3CA were associated with poor prognosis and segregated with the aggressive transcriptional cluster. Moreover, samples with PIK3CA amplification carried signatures associated with in vitro activation of PI3 kinase (PI3K), a signature that was shared by aggressive tumors without PIK3CA amplification. Tumors with loss of PTEN expression or PIK3CA overexpression that did not have PIK3CA amplification also shared the PI3K activation signature, high protein expression of the PI3K pathway member STMN1, and an aggressive phenotype in test and validation datasets. However, mutations of PTEN or PIK3CA were not associated with the same expression profile or aggressive phenotype. STMN1 expression had independent prognostic value. The results affirm the utility of systematic characterization of the cancer genome in clinically annotated specimens and suggest the particular importance of the PI3K pathway in patients who have aggressive endometrial cancer.
Collapse
Affiliation(s)
- H. B. Salvesen
- aDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway;
- bDepartment of Clinical Medicine, University of Bergen, 5020 Bergen, Norway;
- 1To whom correspondence may be addressed. E-mail: , , or
| | - S. L. Carter
- cThe Harvard and MIT Division of Health Sciences and Technology, Cambridge, MA 02142;
- dThe Broad Institute of Harvard and MIT, Cambridge, MA 02142;
| | - M. Mannelqvist
- eThe Gade Institute, Section for Pathology, University of Bergen, 5020 Bergen, Norway;
| | - A. Dutt
- dThe Broad Institute of Harvard and MIT, Cambridge, MA 02142;
- fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115;
| | - G. Getz
- dThe Broad Institute of Harvard and MIT, Cambridge, MA 02142;
| | - I. M. Stefansson
- eThe Gade Institute, Section for Pathology, University of Bergen, 5020 Bergen, Norway;
- gDepartment of Pathology, Haukeland University Hospital, 5020 Bergen, Norway;
| | - M. B. Raeder
- aDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway;
- bDepartment of Clinical Medicine, University of Bergen, 5020 Bergen, Norway;
| | - M. L. Sos
- hMax Planck-Institute for Neurological Research, and Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, 509315 Cologne, Germany;
| | - I. B. Engelsen
- aDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway;
| | - J. Trovik
- aDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway;
- bDepartment of Clinical Medicine, University of Bergen, 5020 Bergen, Norway;
| | - E. Wik
- aDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway;
- bDepartment of Clinical Medicine, University of Bergen, 5020 Bergen, Norway;
| | - H. Greulich
- dThe Broad Institute of Harvard and MIT, Cambridge, MA 02142;
- fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115;
- iDepartment of Medicine, Brigham and Women's Hospital, Boston, MA 02115;
- jDepartment of Medicine, Harvard Medical School, Boston, MA 02115;
| | - T. H. Bø
- kDepartment for Informatics and Computational Biology Unit, University of Bergen, 5020 Bergen, Norway;
| | - I. Jonassen
- kDepartment for Informatics and Computational Biology Unit, University of Bergen, 5020 Bergen, Norway;
| | - R. K. Thomas
- hMax Planck-Institute for Neurological Research, and Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, 509315 Cologne, Germany;
- lChemical Genomics Center of the Max Planck Society, 44227 Dortmund, Germany;
- mDepartment of Internal Medicine and Center of Integrated Oncology, University of Cologne, 50931 Cologne, Germany;
| | - T. Zander
- hMax Planck-Institute for Neurological Research, and Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne, 509315 Cologne, Germany;
| | - L. A. Garraway
- dThe Broad Institute of Harvard and MIT, Cambridge, MA 02142;
- fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115;
- iDepartment of Medicine, Brigham and Women's Hospital, Boston, MA 02115;
- jDepartment of Medicine, Harvard Medical School, Boston, MA 02115;
- nCenter for Cancer Genome Discovery, Dana–Farber Cancer Institute, Boston, MA 02115;
| | - A. M. Øyan
- eThe Gade Institute, Section for Pathology, University of Bergen, 5020 Bergen, Norway;
| | - W. R. Sellers
- oNovartis Institutes for Biomedical Research, Cambridge, MA 02139; and
| | - K. H. Kalland
- eThe Gade Institute, Section for Pathology, University of Bergen, 5020 Bergen, Norway;
- oNovartis Institutes for Biomedical Research, Cambridge, MA 02139; and
| | - M. Meyerson
- dThe Broad Institute of Harvard and MIT, Cambridge, MA 02142;
- fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115;
- qDepartment of Pathology, Harvard Medical School, Boston, MA 02115
| | - L. A. Akslen
- eThe Gade Institute, Section for Pathology, University of Bergen, 5020 Bergen, Norway;
- gDepartment of Pathology, Haukeland University Hospital, 5020 Bergen, Norway;
- 1To whom correspondence may be addressed. E-mail: , , or
| | - R. Beroukhim
- dThe Broad Institute of Harvard and MIT, Cambridge, MA 02142;
- fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115;
- iDepartment of Medicine, Brigham and Women's Hospital, Boston, MA 02115;
- jDepartment of Medicine, Harvard Medical School, Boston, MA 02115;
- 1To whom correspondence may be addressed. E-mail: , , or
| |
Collapse
|
64
|
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-75. [PMID: 18948947 PMCID: PMC2694412 DOI: 10.1038/nature07423] [Citation(s) in RCA: 2026] [Impact Index Per Article: 126.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2008] [Accepted: 09/10/2008] [Indexed: 02/08/2023]
Abstract
Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.
Collapse
Affiliation(s)
- Li Ding
- The Genome Center at Washington University, Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63108, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
65
|
Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008; 105:8713-7. [PMID: 18552176 PMCID: PMC2438391 DOI: 10.1073/pnas.0803379105] [Citation(s) in RCA: 284] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma. These FGFR2 mutations, many of which are identical to mutations associated with congenital craniofacial developmental disorders, are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells. Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma.
Collapse
Affiliation(s)
- Amit Dutt
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Helga B. Salvesen
- ‡Department of Clinical Medicine and
- §Obstetrics and Gynecology, Haukeland University Hospital, N-5020 Bergen, Norway; and
| | - Tzu-Hsiu Chen
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Alex H. Ramos
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | | | - Charlie Hatton
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Richard Nicoletti
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Wendy Winckler
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Rupinder Grewal
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Megan Hanna
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Nicolas Wyhs
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Liuda Ziaugra
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | | | - Jone Trovik
- ‡Department of Clinical Medicine and
- §Obstetrics and Gynecology, Haukeland University Hospital, N-5020 Bergen, Norway; and
| | - Ingeborg B. Engelsen
- ‡Department of Clinical Medicine and
- §Obstetrics and Gynecology, Haukeland University Hospital, N-5020 Bergen, Norway; and
| | - Ingunn M. Stefansson
- ‖The Gade Institute, Section for Pathology, University of Bergen, N-5020 Bergen, Norway;
- Departments of **Pathology and
| | | | | | | | - Lars A. Akslen
- ‖The Gade Institute, Section for Pathology, University of Bergen, N-5020 Bergen, Norway;
- Departments of **Pathology and
| | - Stacey Gabriel
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Kwok-Kin Wong
- *Department of Medical Oncology and
- ††Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
| | | | - Matthew Meyerson
- *Department of Medical Oncology and
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- §§Department of Pathology, Harvard Medical School, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
- ¶¶To whom correspondence may be addressed. E-mail: or
| | - Heidi Greulich
- *Department of Medical Oncology and
- ††Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
- ¶¶To whom correspondence may be addressed. E-mail: or
| |
Collapse
|
66
|
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong K, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39:567-567. [DOI: 10.1038/ng0407-567a] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
67
|
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39:347-51. [PMID: 17293865 DOI: 10.1038/ng1975] [Citation(s) in RCA: 784] [Impact Index Per Article: 46.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2006] [Accepted: 01/11/2007] [Indexed: 02/07/2023]
Abstract
Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression. However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability. Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples. This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation. Moreover, we identified previously unrecognized oncogene mutations in several tumor types and observed an unexpectedly high number of co-occurring mutations. These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention.
Collapse
Affiliation(s)
- Roman K Thomas
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
68
|
Abstract
PURPOSE OF REVIEW Classifying tumors and identifying therapeutic targets requires a description of the genetic changes underlying cancer. Single nucleotide polymorphism (SNP) arrays provide a high-resolution platform for describing several types of genetic changes simultaneously. With the resolution of these arrays increasing exponentially, they are becoming increasingly powerful tools for describing the genetic events underlying cancer. RECENT FINDINGS The ability to map loss of heterozygosity (LOH) and overall copy number variations using SNP arrays is known. Techniques have recently been developed to map LOH at high resolution in the absence of paired normal data. Copy number variations described by SNP array studies are now reaching resolutions enabling the identification of novel oncogenes and tumor suppressor genes. The ability to determine allele-specific copy number changes has only recently been described. Moreover, SNP arrays offer a high-throughput platform for large-scale association studies that are likely to lead to the identification of multiple germline variants that predispose to cancer. SUMMARY SNP arrays are an ideal platform for identifying both somatic and germline genetic variants that lead to cancer. They provide a basis for DNA-based cancer classification and help to define the genes being modulated, improving understanding of cancer genesis and potential therapeutic targets.
Collapse
Affiliation(s)
- Amit Dutt
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge 02142, USA
| | | |
Collapse
|
69
|
Abstract
Human lung cancer is responsible for approximately 30% of all cancer deaths worldwide with >160,000 deaths in the United States alone annually. Recent advances in the identification of novel mutations relevant to lung cancer from a myriad of genomic studies might translate into meaningful diagnostic and therapeutic progress. Towards this end, a genetic model animal system that can validate the oncogenic roles of these mutations in vivo would facilitate the understanding of the pathogenesis of lung cancer as well as provide ideal preclinical models for targeted therapy testing. The mouse is a promising model system, as complex human genetic traits causal to lung cancer, from inherited polymorphisms to somatic mutations, can be recapitulated in its genome via genetic manipulation. We present here a brief overview of the existing mouse models of lung cancers and the challenges and opportunities for building the next generation of lung cancer mouse models.
Collapse
Affiliation(s)
- Amit Dutt
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
| | | |
Collapse
|
70
|
Murtaza I, Mushtaq D, Margoob MA, Dutt A, Wani NA, Ahmad I, Bhat ML. A study on p53 gene alterations in esophageal squamous cell carcinoma and their correlation to common dietary risk factors among population of the Kashmir valley. World J Gastroenterol 2006; 12:4033-7. [PMID: 16810754 PMCID: PMC4087716 DOI: 10.3748/wjg.v12.i25.4033] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
AIM To systematically examine the extent of correlation of risk factors, such as age, consumed dietary habit and familial predisposition with somatic Tp53 molecular lesion causal to elevate carcinogenesis severity of esophageal squamous cell carcinoma (ESCC) among the Kashmiri population of Northern India. METHODS All cases (n = 51) and controls (n = 150) were permanent residents of the Kashmir valley. Genetic alterations were determined in exons 5-8 of Tp53 tumor suppressor gene among 45 ESCC cases histologically confirmed by PCR-SSCP analysis. Data for individual cancer cases (n = 45) and inpatient controls (n = 150) with non-cancer disease included information on family history of cancer, thirty prevailing common dietary risk factors along with patient's age group. Correlation of genetic lesion in p53 exons to animistic data from these parameters was generated by Chi-square test to all 45 histologically confirmed ESCC cases along with healthy controls. RESULTS Thirty-five of 45 (77.8%) histologically characterized tumor samples had analogous somatic mutation as opposed to 1 of 45 normal sample obtained from adjacent region from the same patient showed germline mutation. The SSCP analysis demonstrated that most common p53 gene alterations were found in exon 6 (77.7%), that did not correlate with the age of the individual and clinicopathological parameters but showed significant concordance (P<0.05) with familial history of cancer (CD = 58), suggesting germline predisposition at an unknown locus, and dietary habit of consuming locally grown Brassica vegetable "Hakh" (CD = 19.5), red chillies (CD = 20.2), hot salty soda tea (CD = 2.37) and local baked bread (CD = 1.1). CONCLUSION Our study suggests that somatic chromosomal mutations, especially in exon 6 of Tp53 gene, among esophageal cancer patients of an ethnically homogenous population of Kashmir valley are closely related to continued exposure to various common dietary risk factors, especially hot salty tea, meat, baked bread and "Hakh", that are rich in nitrosoamines and familial cancer history.
Collapse
Affiliation(s)
- Imtiyaz Murtaza
- Division of PHT, SKUAST (K), Shalimar Campus, Srinagar, Kashmir, 191121 (J and K), India.
| | | | | | | | | | | | | |
Collapse
|
71
|
Murtaza I, Marra G, Schlapbach R, Patrignani A, Künzli M, Wagner U, Sabates J, Dutt A. A preliminary investigation demonstrating the effect of quercetin on the expression of genes related to cell-cycle arrest, apoptosis and xenobiotic metabolism in human CO115 colon-adenocarcinoma cells using DNA microarray. Biotechnol Appl Biochem 2006; 45:29-36. [PMID: 16640504 DOI: 10.1042/ba20060044] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The role of the natural dietary flavonoid chemical quercetin (an antioxidant) in the prevention and treatment of colon cancer is receiving a great deal of attention. However, little is known about the molecular mechanisms of action of this flavonoid. In the present study, whole genome DNA microarrays were used to evaluate the effect of quercetin on gene expression in the CO115 colon-adenocarcinoma cell line with the completely deleted chromosome 18 harbouring the SMAD4 tumour-suppressor gene related to colon carcinogenesis. The study demonstrated that quercetin, widely present in fruit and vegetables, inhibited the growth of CO115 cells at 100 microM concentration in both the G(1)/S and the G(2)/M phases by modulating cell-cycle and apoptosis-related genes. Differential changes in accumulation of transcripts analysed for cells treated with 100 microM quercetin for 24 and 48 h in three independent repeated experiments revealed 5060-7000 differentially expressed genes. This means that quercetin probably does have a broad modulatory effect on gene expression in colon cancer. Out of these differentially expressed genes, the expression of 35 and 23 unique set of genes involved in cell-cycle control, apoptosis and xenobiotic metabolism were significantly altered after 24 and 48 h quercetin treatment respectively. Our results represent a novel aspect of the biological profile of quercetin that induces cell-cycle arrest through modulation of cell-cycle-related and apoptosis genes. The present study demonstrates a new step in elucidating the underlying molecular mechanisms of the antitumour action of quercetin, which could become a chemopreventive or chemotherapeutic agent for colon cancer.
Collapse
Affiliation(s)
- Imtiyaz Murtaza
- Biochemistry and Molecular Biotechnology Laboratory, Division of PHT, SK University of Agricultural Sciences and Technology, Shalimar Campus, Srinagar, Kashmir, India.
| | | | | | | | | | | | | | | |
Collapse
|
72
|
Murtaza I, Dutt A, Mushtaq D, Ali A. Molecular cloning and genetic analysis of functional merB gene from indian isolates of Escherichia coli. Curr Microbiol 2005; 51:297-302. [PMID: 16211434 DOI: 10.1007/s00284-005-0013-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2005] [Accepted: 05/30/2005] [Indexed: 02/08/2023]
Abstract
Studies were carried out to characterize organomercurial lyase genes from wild type mercury-resistant Escherichia coli isolates, previously collected from five geographically distinct regions of the Indian subcontinent. PCR amplification followed by DNA sequencing of amplified fragments showed three merB identical to the previously characterized mer B from E. coli pR831b that were thus considered as the same gene. The remaining two genes derived from E. coli isolates of an almost mercury-free site (Dal lake, Kashmir) and designated as pIAAD3 merB and pIAAD14 merB showed slight variation (2%) at base. However, this variation in pIAAD3 due to the absence of base "T" at 479 position results in complete frame shift and the predicted MerB-like polypeptide derived from it showed 21.53% divergent at its C terminal end from the previously characterized pR831b MerB. The expression profile of pIAAD3 merB in pQE30 and pUC18 vectors each demonstrated 22.2 kDa proteins. The induced DH5alpha E. coli cells possessing pIAAD3 merB cloned in pUC18 vector split phenyl mercuric acetate (PMA) into benzene and inorganic mercury efficiently, thus giving a clue that the expressed gene product is biologically active. The current study suggests that such genetic changes may take place in the continued absence of mercury pressure, and with such modifications, they finally break down to act as vestigial remnants. Further work is going on in our lab to exploit pIAAD3 merB for the bioremediation of mercury-polluted sites.
Collapse
Affiliation(s)
- Imtiyaz Murtaza
- Molecular Biotechnology and Biochemistry Laboratory, Division of PHT, S.K University of Agricultural Sciences and Technology of Kashmir, Shalimar Campus, Srinagar, Kashmir, India.
| | | | | | | |
Collapse
|
73
|
Dutt A, Canevascini S, Froehli-Hoier E, Hajnal A. EGF signal propagation during C. elegans vulval development mediated by ROM-1 rhomboid. PLoS Biol 2004; 2:e334. [PMID: 15455032 PMCID: PMC519001 DOI: 10.1371/journal.pbio.0020334] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2004] [Accepted: 08/03/2004] [Indexed: 02/05/2023] Open
Abstract
During Caenorhabditis elegans vulval development, the anchor cell (AC) in the somatic gonad secretes an epidermal growth factor (EGF) to activate the EGF receptor (EGFR) signaling pathway in the adjacent vulval precursor cells (VPCs). The inductive AC signal specifies the vulval fates of the three proximal VPCs P5.p, P6.p, and P7.p. The C. elegans Rhomboid homolog ROM-1 increases the range of EGF, allowing the inductive signal to reach the distal VPCs P3.p, P4.p and P8.p, which are further away from the AC. Surprisingly, ROM-1 functions in the signal-receiving VPCs rather than the signal-sending AC. This observation led to the discovery of an AC-independent activity of EGF in the VPCs that promotes vulval cell fate specification and depends on ROM-1. Of the two previously reported EGF splice variants, the longer one requires ROM-1 for its activity, while the shorter form acts independently of ROM-1. We present a model in which ROM-1 relays the inductive AC signal from the proximal to the distal VPCs by allowing the secretion of the LIN-3L splice variant. These results indicate that, in spite of their structural diversity, Rhomboid proteins play a conserved role in activating EGFR signaling in C. elegans, Drosophila, and possibly also in mammals.
Collapse
Affiliation(s)
- Amit Dutt
- 1Zoologisches Institut, Universität ZurichZurichSwitzerland
| | | | | | - Alex Hajnal
- 1Zoologisches Institut, Universität ZurichZurichSwitzerland
| |
Collapse
|
74
|
Murtaza I, Dutt A, Ali A. Relationship between the persistence of mer operon sequences in Escherichia coli and their resistance to mercury. Curr Microbiol 2002; 44:178-83. [PMID: 11821925 DOI: 10.1007/s00284-001-0085-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2001] [Accepted: 06/27/2001] [Indexed: 02/08/2023]
Abstract
Studies related to geographic distribution of E. coli carrying mer operon sequences were carried out on the Indian subcontinent. Out of the 80 E. coli isolates, collected from five geographically distinct regions of India, 68 were found to be resistant to one or the other heavy metal used in the study. Among these isolates, 36 were found to be resistant to the inorganic form (HgCl2) and only 5 to resist both the inorganic and organic forms of mercury. Colony hybridization studies revealed 35 isolates out of 68 to hybridize with the probe. Interestingly, some of the mercury-sensitive isolates (Hgs), especially from the Dal Lake, were found positive in hybridization studies. These findings, supported by mercury volatilization studies, indicate the presence of nonfunctional/vestigial mer sequences in the isolates collected from different environments. On the other hand, few of the mercury-resistant isolates (Hgr) from the Yamuna River did not show any sign of hybridization. Further, volatilization studies also indicated an alternate mode of resistance mechanism operating in them. The studies demonstrate that the mer operon sequences share very high homology among the E. coli isolates collected from different geographical locations, and this metal resistance may be a genetic character that arose from a common ancestral background.
Collapse
Affiliation(s)
- Imtiyaz Murtaza
- Gene Expression Laboratory, Department of Biosciences, Jamia Millia Islamia, New Delhi-110 025, India
| | | | | |
Collapse
|